New Sjögren's drug shows promise in early safety trial
NCT ID NCT06484855
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 24 times
Summary
This early-stage study tested a new drug called IBI355 in 30 adults with primary Sjögren's syndrome, an autoimmune disease that causes dry eyes and mouth. The main goal was to see if the drug is safe and how the body processes it. Participants received multiple doses, and researchers monitored side effects and drug levels in the blood.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SJÖGREN'S SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, 230001, China
Conditions
Explore the condition pages connected to this study.